Phosphocalcic cement composition comprising blood

Abstract

A bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed.

1 . A bone cement paste comprising a powder component and a liquid component comprising blood;
 wherein the powder component comprises, in relation to the total weight of the powder component:   at least 70% by weight of α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, wherein said average size is the mean equivalent diameter of said particles measured by LASER diffraction analysis; and   at least 5% by weight of calcium-deficient apatite (CDA);   wherein the liquid component (L)/powder component (P) ratio is between 0.3 and 0.7 mL/g; and   wherein the bone cement paste has a setting time ranging from 10 minutes to 72 hours.   
     
     
         2 . The bone cement paste according to  claim 1 , wherein the liquid component is blood. 
     
     
         3 . The bone cement paste according to  claim 1 , wherein the α-tricalcium phosphate (α-TCP) particles have an average size greater than or equal to 10 μm. 
     
     
         4 . The bone cement paste according to  claim 1 , wherein the powder component further comprises at least one calcium phosphate compound selected from the group consisting of hydroxyapatite (HA), amorphous calcium phosphate (ACP), monocalcium phosphate anhydrous (MCPA), monocalcium phosphate monohydrate (MCPM), dicalcium phosphate dihydrate (DCPD), dicalcium phosphate anhydrous (DCPA), β-tricalcium phosphate (β-TCP), tetracalcium phosphate (TTCP), and mixtures thereof. 
     
     
         5 . The bone cement paste according to  claim 4 , wherein the calcium phosphate compound is dicalcium phosphate anhydrous (DCPA). 
     
     
         6 . The bone cement paste according to  claim 5 , wherein the powder component comprises at least 1% by weight of DCPA, in relation to the total weight of the powder component. 
     
     
         7 . The bone cement paste according to  claim 1 , wherein the powder component further comprises at least one cellulose ester. 
     
     
         8 . The bone cement paste according to  claim 7 , wherein the cellulose ester is selected from the group consisting of hydroxypropylmethylcellulose (HPMC) and carboxymethylcellulose (CMC). 
     
     
         9 . The bone cement paste according to  claim 7 , wherein the powder component comprises between 0.1% and 5% by weight of the cellulose ester, in relation to the total weight of the powder component. 
     
     
         10 . The bone cement paste according to  claim 1 , wherein the liquid component (L)/powder component (P) ratio is between 0.4 and 0.6 mug. 
     
     
         11 . The bone cement paste according to  claim 10 , wherein the liquid component (L)/powder component (P) ratio is 0.45 or 0.55 mL/g. 
     
     
         12 . An apatitic calcium phosphate cement resulting from the setting of the bone cement paste according to  claim 1 , wherein the apatitic calcium phosphate cement has a compressive strength between 2 MPa and 15 MPa. 
     
     
         13 . The apatitic calcium phosphate cement of  claim 12 , further including a contrasting agent for X-ray imaging or MRI, and/or further including a therapeutic agent or a compound that will present a therapeutic effect. 
     
     
         14 . The apatitic calcium phosphate cement of  claim 12 , wherein the α-tricalcium phosphate (α-TCP) particles have an average size greater than or equal to 10 μm. 
     
     
         15 . An apatitic calcium phosphate cement obtainable by a process comprising the following steps:
 the preparation of a bone cement paste by mixing a powder component and a liquid component comprising blood, and   wherein the powder component comprises, in relation to the total weight of the powder component:   at least 70% by weight of α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, wherein said average size is the mean equivalent diameter of said particles measured by LASER diffraction analysis; and   at least 5% by weight of calcium-deficient apatite (CDA);   wherein the liquid component (L)/powder component (P) ratio is between 0.3 and 0.7 mL/g; and   wherein the bone cement paste has a setting time ranging from 10 minutes to 72 hours; and   the setting of said bone cement paste;   wherein the apatitic calcium phosphate cement has a compressive strength between 2 MPa and 15 MPa.   
     
     
         16 . The apatitic calcium phosphate cement of  claim 15 , wherein the α-tricalcium phosphate (α-TCP) particles have an average size greater than or equal to 10 μm. 
     
     
         17 . A method for filling a dental or bony defect, comprising injecting the apatitic calcium phosphate cement according to  claim 12  into said defect. 
     
     
         18 . An implant comprising the apatitic calcium phosphate cement according to  claim 12 . 
     
     
         19 . A method for promoting spine fusion inside intersomatic cages, comprising:
 placing a fusion cage between two vertebral bodies, and   injecting the bone cement paste according to  claim 1  inside the fusion cage.   
     
     
         20 . A kit for spinal fusion, comprising:
 a fusion cage, and   a bone cement paste according to  claim 1 .